

**REPORT TO THE LEGISLATURE**  
**Pursuant to P.A. 107 of**  
**2017 Article V, Section 807**  
**Hepatitis C treatment Report**  
**3rd Qtr-FY18**

**Section 807:** The funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment. On a quarterly basis, the department shall issue a report to the senate and house appropriations subcommittees on corrections, the senate and house fiscal agencies, the legislative corrections ombudsman, and the state budget office, showing for the previous 4 quarters the total amount spent on specialty medication for the treatment of Hepatitis C, the number of prisoners that were treated, the amount of any rebates that were received from the purchase of specialty medication, and what outstanding rebates are expected to be received.

QTR	# of Prisoners that started treatment during QTR	Total # of prisoners in Treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate rec'd	Total rebate expected
4th qtr 2017	44	105	67	\$ 2,775,875	\$ -	\$ -
1st qtr 2018	102	140	49	\$ 2,486,886	\$ -	\$ -
2nd qtr 2018	116	208	103	\$ 2,601,185	\$ 1,047,227.87*	\$ -
3rd qtr 2018	121	221	108	\$ 2,394,445	\$ -	\$ -

\*residual rebates for Harvoni purchased from Maxor